by Rod Raynovich | Sep 20, 2010 | 2023-24 Life Science Portfolios, BIOgraph
Continuing from Part 1 here are some specific comments on interesting companies. Adeona Pharmaceuticals (AEN) Amex ($0.83) Market Cap $19M, $25M Sh. Outstanding Adeona is a development stage drug Company focused in CNS that in -licenses clinical stage product...
by Rod Raynovich | Aug 2, 2010 | BIOgraph
The Wall Street Journal reported on Friday that Novartis (NVS) will collaborate with Pathwork Diagnostics on the development of biomarkers across a range of cancer types that would capitalize on the trend to “match patients with the right medicines”....
by Rod Raynovich | Jul 26, 2010 | 2023-24 Life Science Portfolios, BIOgraph
The July 25-29 AACC (American Association of Clinical Chemistry) Meeting in Anaheim will have close to 20,000 clinical lab professionals and over 500 exhibitors . A stock rally in the sector was ignited last week by earnings announcements from four major mid-cap...
by Rod Raynovich | Jul 6, 2010 | 2023-24 Life Science Portfolios, BIOgraph
But Path to Market is Still Rife with Hurdles Convergence of Genomics and Medicine At the 2010 BIO Conference in Chicago with about 15,000 attendees there were ten Breakout Sessions on Biomarkers (BM) encompassing Intellectual Property, commercialization,...
by Rod Raynovich | Jun 14, 2010 | RAG
Genomics and Medicine: transformative therapies are coming but diagnostic breakthroughs will lead the way Ten years after the start of the Human Genome Project we have learned a lot about the links between genetics and disease but few direct cures have emerged. The...
by Rod Raynovich | May 12, 2010 | BIOgraph
Genotyping on a Fast Track Direct to Consumer Pathway Genomics is offering a “Health Kit” that reports your genetic risk for 70 diseases such as Cancer,Cardiovascular Disease,RA,and Diabetes. Disease carrier status is included as well as potential genetic...
by Rod Raynovich | May 11, 2010 | RAG
Response Genetics(RGDX) announced a deal today for a non-exclusive license to provide GlaxoSmithKline (GSK) with certain rights to proprietary BRAF mutational analysis technology in human tumor samples. The BRAF gene encodes a protein involved in cell signaling and...
by Rod Raynovich | May 10, 2010 | 2023-24 Life Science Portfolios, BIOgraph
Companion Diagnostics Enable More Targeted Therapy At the 2010 BIO Conference in Chicago with about 15,000 attendees there were ten Breakout Sessions on Biomarkers (BM) encompassing Intellectual Property, commercialization, reimbursement, drug development and...
by Rod Raynovich | Apr 20, 2010 | RAG
Yesterday we presented an overview of the use of Biomarkers(BM’s) for predictive use in the treatment of Lung Cancer. Here are some additional summaries from the American Association for Cancer Research(AACR) meeting on Monday.Researchers from Fox Chase Cancer...
by Rod Raynovich | Apr 19, 2010 | BIOgraph
At yesterday’s AACR (American Association of Cancer Research) Meeting in Washington DC researchers presented results from the Battle Trial which is a hypothesis- driven prospective study that identifies biomarkers(BM’s) to predict tumor response and thus...
